



In the Claims:

This listing of Claims will replace all prior versions, and listings, of Claims in the application.

1. (Previously Presented) A compound of the formula (I)



wherein



each R^A and R^B is independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

each R^C and R^D is independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

each R^E is independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

X is $-NR^1 R^2$;

each R^1 and R^2 is independently selected from the group consisting of hydrogen, C_{1-8} alkyl, C_{1-8} alkoxy, C_{1-8} alkoxycarbonyl, cycloalkyl, cycloalkyl- C_{1-4} alkyl, partially unsaturated carbocyclyl, partially unsaturated carbocyclyl- C_{1-4} alkyl, aryl, ar C_{1-4} alkyl, ar C_{1-4} alkoxy, $-C(O)-C_{1-6}$ alkyl, $-C(O)-$ aryl, $-C(O)-$ ar C_{1-4} alkyl, $-C(O)O-$ cycloalkyl, $-C(O)O-$ aryl, -

$\text{C}(\text{O})\text{O}-\text{arC}_{1-4}\text{alkyl}$ and $-\text{C}(\text{O})\text{O}-(\text{partially unsaturated carbocyclyl})$; wherein the $\text{C}_{1-8}\text{alkyl}$, cycloalkyl, partially unsaturated carbocyclyl, aryl or $\text{arC}_{1-8}\text{alkyl}$ group, whether alone or part of a substituent group, is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxy}$, trifluoromethyl, trifluoromethoxy, nitro, cyano, $-\text{C}(\text{O})-\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxycarbonyl}$, $\text{N}(\text{R}^E)_2$, $\text{N}(\text{R}^E)_2-\text{C}_{1-4}\text{alkyl}$, $\text{N}(\text{R}^E)-\text{C}(\text{O})\text{C}(\text{CH}_3)_3$, $-\text{C}_{1-4}\text{alkyl}-\text{N}(\text{R}^E)-\text{C}(\text{O})\text{O}-\text{C}_{1-4}\text{alkyl}$ and $-\text{N}(\text{R}^E)-\text{C}(\text{O})\text{O}-\text{C}_{1-4}\text{alkyl}$, aryl, aryloxy, cycloalkyl, heteroaryl, aryl substituted heteroarylamino sulfonyl or $\text{C}_{1-6}\text{alkylthio}$;

R^3 is aryl; wherein the aryl is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxy}$, trifluoromethyl, trifluoromethoxy, nitro, cyano or $\text{N}(\text{R}^E)_2$;

n is an integer from 0 to 2;

R^4 is selected from the group consisting of hydroxy, $\text{C}_{1-4}\text{alkyl}$ and hydroxy substituted $\text{C}_{1-4}\text{alkyl}$;

m is an integer from 0 to 1;

L^1 is selected from the group consisting of $\text{C}_{1-6}\text{alkyl}$ and $\text{C}_{3-6}\text{alkenyl}$; wherein the double bond of the $\text{C}_{3-6}\text{alkenyl}$ group is at least one carbon atom removed from the attachment point to the N atom; and wherein the $\text{C}_{1-6}\text{alkyl}$ or $\text{C}_{3-6}\text{alkenyl}$ group is optionally substituted with one to two substituents independently selected from hydroxy, fluoro, $\text{C}_{1-6}\text{alkyl}$, fluorinated $\text{C}_{1-6}\text{alkyl}$ or $\text{C}_{1-6}\text{alkoxy}$;



is selected from the group consisting of phenyl, naphthyl and acenaphthyl;

p is an integer from 0 to 5;

R^5 is selected from the group consisting of hydroxy, carboxy, halogen, $\text{C}_{1-6}\text{alkyl}$, hydroxy substituted $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{1-6}\text{alkoxy}$, nitro, cyano, NR^1R^2 , trifluoromethyl, trifluoromethoxy, $\text{C}_{1-4}\text{alkoxycarbonyl}$, $-\text{SO}-\text{NR}^1\text{R}^2$, $-\text{SO}_2-\text{NR}^1\text{R}^2$ and $-\text{C}(\text{O})-\text{NR}^1\text{R}^2$;

q is 0;


R^6 is selected from the group consisting of $-(\text{L}^2)_{0-1}-\text{R}^7$;

L^2 is selected from the group consisting of $-C_{1-6}alkyl-$, $-C_{2-4}alkenyl-$, $-C_{2-6}alkynyl-$, $-O-$, $-S-$, $-NH-$, $-N(C_{1-4}alkyl)-$, $-C_{1-6}alkyl-O-$, $-C_{1-6}alkyl-S-$, $-O-C_{1-6}alkyl-$, $-S-C_{1-6}alkyl-$, $-O-C_{2-6}alkyl-O-$, $-S-C_{2-6}alkyl-S-$, $-SO_2-$, $-SO_2NH-$, $-SO_2N(C_{1-4}alkyl)-$, $-NH-SO_2-$, $-N(C_{1-4}alkyl)-SO_2-$, $-C(O)-O-$ and $-O-C(O)-$;

R^7 is selected from the group consisting of aryl, partially unsaturated carbocyclyl, cycloalkyl, heteroaryl and heterocycloalkyl; wherein the aryl, partially unsaturated carbocyclyl, cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from hydroxy, carboxy, halogen, $C_{1-6}alkyl$, $C_{1-6}alkoxy$, nitro, cyano, $N(R^E)_2$, trifluoromethyl, trifluoromethoxy, $C_{1-4}alkoxycarbonyl$, $-SO_2-N(R^E)_2$ and $-C(O)-N(R^E)_2$;

or a pharmaceutically acceptable salt thereof.

2. (Previously Presented) A compound as in Claim 1 wherein



R^0 is selected from the group consisting of

each R^C and R^D is independently selected from hydrogen and $C_{1-4}alkyl$;
 X is $-NR^1R^2$;

R^1 is selected from the group consisting of hydrogen, $C_{1-4}alkyl$, $C_{1-4}alkoxy$, $C_{1-4}alkoxycarbonyl$, aryl, $arC_{1-4}alkyl$, $arC_{1-4}alkyloxy$, cycloalkyl-alkyl and $C(O)-C_{1-4}alkyl$;

wherein the $C_{1-4}alkyl$, aryl, $arC_{1-4}alkyl$ or cycloalkyl group, whether alone or part of a substituent group, is optionally substituted with one to three substituents independently selected from halogen, hydroxy, carboxy, $C_{1-4}alkyl$, $C_{1-4}alkoxy$, $C_{1-4}alkoxycarbonyl$, $N(R^E)_2$, $N(R^E)_2-C_{1-4}alkyl$, $N(R^E)-C(O)OC(CH_3)_3$, nitro, trifluoromethyl, trifluoromethoxy, phenyl, phenoxy, heteroaryl, cycloalkyl, 1-phenyl-pyrazol-2-yl-aminosulfonyl or $C_{1-4}alkylthio$;

R^2 is selected from the group consisting of hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, cycloalkyl, cycloalkyl- C_{1-4} alkyl, aryl, ar C_{1-4} alkyl, ar C_{1-4} alkyloxy, partially unsaturated carbocyclyl, partially unsaturated carbocyclyl- C_{1-4} alkyl, $-C(O)-C_{1-4}$ alkyl, $-C(O)-$ aryl, $-C(O)-arC_{1-4}$ alkyl, $-C(O)O-$ cycloalkyl and $-C(OO)-C_{1-4}$ alkyl;

wherein the C_{1-4} alkyl, aryl, ar C_{1-4} alkyl, partially unsaturated carbocyclyl or cycloalkyl group, whether alone or part of a substituent group, is optionally substituted with one to three substituents independently selected from halogen, hydroxy, carboxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl, $N(R^E)_2$, $N(R^E)_2-C_{1-4}$ alkyl, $(CH_3)_3COC(O)-N(R^E)-C_{1-4}$ alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, phenyl, phenoxy, heteroaryl, cycloalkyl, 1-phenyl substituted heteroaryl-aminosulfonyl, $-C(O)-C_{1-4}$ alkyl or C_{1-4} alkylthio;

R^3 is aryl; wherein the aryl is optionally substituted with one to three substituents independently selected from halogen, hydroxy, carboxy, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethyl, trifluoromethoxy, nitro, cyano or $N(R^E)_2$;


n is an integer from 0 to 1;

L^1 is C_{1-4} alkyl; wherein the C_{1-4} alkyl group is optionally substituted with one to two substituents independently selected from hydroxy, fluoro, C_{1-4} alkyl, fluorinated C_{1-4} alkyl or C_{1-4} alkoxy;

R^5 is selected from the group consisting of hydroxy, carboxy, halogen, C_{1-4} alkyl, C_{1-4} alkoxy, nitro, cyano, $N(R^E)_2$, trifluoromethyl, trifluoromethoxy, C_{1-4} alkoxycarbonyl, $-SO-N(R^E)_2$, $-SO_2-N(R^E)_2$ and $-C(O)-N(R^E)_2$;

or a pharmaceutically acceptable salt thereof.

3. (Previously Presented) A compound as in Claim 2 wherein



each R^A , R^B , R^C and R^D is hydrogen;

X is $-NR^1R^2$;

R^1 is selected from the group consisting of hydrogen, C_{1-4} alkyl, C_{1-4} alkoxycarbonyl, arC_{1-4} alkyl and $C(O)-C_{1-4}$ alkyl;

wherein the C_{1-4} alkyl or aryl group, whether alone or part of a substituent group, is optionally substituted with one to two substituents independently selected from carboxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl, $N(R^E)_2$ or $N(R^E)-C(O)OC(CH_3)_3$;

R^2 is selected from the group consisting of hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, cycloalkyl, aryl, arC_{1-4} alkyl, arC_{1-4} alkyloxy, partially unsaturated carbocyclyl, partially unsaturated carbocyclyl- C_{1-4} alkyl, cycloalkyl- C_{1-4} alkyl, $-C(O)arC_{1-4}$ alkyl, $-C(OO)-$ cycloalkyl and $-C(O)O-C_{1-4}$ alkyl;

wherein the C_{1-4} alkyl, aryl, arC_{1-4} alkyl, partially unsaturated carbocyclyl or cycloalkyl group, whether alone or part of a substituent group, is optionally substituted with one to three substituents independently selected from halogen, hydroxy, carboxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl, $N(R^E)_2$, $N(R^E)_2-C_{1-4}$ alkyl, $(CH_3)_3CO-C(O)-N(R^E)-C_{1-4}$ alkyl, nitro, trifluoromethyl, trifluoromethoxy, phenyl, phenoxy, heteroaryl, cycloalkyl, 1-phenyl-pyrazol-2-yl-aminosulfonyl or C_{1-4} alkylthio;

R^3 is aryl; wherein the aryl group is optionally substituted with one or more substituents independently selected from halogen;

n is 0;

L^1 is C_{1-4} alkyl;


R^5 is selected from the group consisting of halogen, C_{1-4} alkyl and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

4. (Previously Presented) A compound as in Claim 3 wherein


R^0 is selected from the group consisting of $-CH_2-CH(OH)-CH_2-X$ and $-CH_2-CH_2-CH(OH)-CH_2-X$;

X is $-NR^1R^2$;

R^1 is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, n-butyl, t-butyl, amino-n-propyl, dimethylaminoethyl, benzyl, phenylethyl, 4-methyl-benzyl,





, 2-(3,4-dimethoxy-phenyl)ethyl, 3-methyl-phenyl, ethoxy-carbonyl-methyl, 2-amino-2-methoxycarbonyl-ethyl, t-butoxycarbonyl



and

R^2 is selected from the group consisting of hydrogen, methyl, methoxy, ethyl, carboxy-methyl, ethoxycarbonylmethyl, 2,2,2-trifluoroethyl, ethoxy, dimethylaminoethyl, t-butoxycarbonylamino-ethyl, n-butyl, t-butyl, n-propyl, 3-hydroxy-n-propyl, 3-methoxy-n-propyl, methylamino-n-propyl, dimethylamino-n-propyl, di(n-butyl)amino-n-propyl, t-butoxycarbonylamino-n-propyl, 3-phenyl-n-propyl, 3-(2-pyridyl)-n-propyl, t-butoxycarbonyl, cyclopropyl, phenyl, 4-fluorophenyl, 4-methylphenyl, 3,4-dimethoxyphenyl, 2-aminophenyl, 4-biphenyl, 2-ethoxyphenyl, 4-((1-phenyl-pyrazol-2-yl)-aminosulfonyl)-phenyl, 4-cyclohexylphenyl, 4-(aminoethyl)phenyl, 4-(t-butoxycarbonylamino-ethyl)-phenyl, -CH(CH₃)-phenyl, benzyl, benzyloxy, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, 2-methoxybenzyl, 3-methoxybenzyl, 4-methoxybenzyl, 2-ethoxybenzyl, 3-ethoxybenzyl, 2-bromobenzyl, 3-bromobenzyl, 4-bromobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3-iodobenzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-trifluoromethylbenzyl, 3-trifluoromethylbenzyl, 4-trifluoromethylbenzyl, 4-trifluoromethoxybenzyl, 4-methoxycarbonylbenzyl, 2,3-dimethoxybenzyl, 2,4-dichlorobenzyl, 3,4-dichlorobenzyl, 2,4-difluorobenzyl, 2,5-difluorobenzyl, 3,4-difluorobenzyl, 3,4,5-trimethoxybenzyl, 2,4,6-trimethoxybenzyl, 4-carboxybenzyl, 3-nitrobenzyl, 4-nitrobenzyl, 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl, 3,5-dimethoxybenzyl, 3,4-difluorobenzyl, 3,5-di(trifluoromethyl)benzyl, 4-(dimethylamino)benzyl, 2-phenylethyl, 2-(4-bromophenyl)ethyl, 2-(3-methoxyphenyl)ethyl, 2-(4-methoxyphenyl)ethyl, 2-(3,4-dimethoxyphenyl)ethyl, 2-(2-nitro-4,5-dimethoxy-phenyl)ethyl, 1-adamantanyl, 1-adamantanyl-methyl, 1-naphthyl, 1-

naphthyl-methyl, 1-phenyl-2-(t-butoxycarbonyl)ethyl, -C(O)-C(OCH₃)(CF₃)-phenyl, -



, 2S-hydroxy-S-cyclopentyl-methyl, 2S-hydroxy-S-cyclohexyl-methyl, 2S-hydroxy-S-cycloheptyl-methyl, 2-phenoxy-ethyl and 2-phenyl-cyclopropyl;

R³ is selected from the group consisting of phenyl and 4-fluorophenyl;

L¹ is selected from the group consisting of -CH₂-, -CH(CH₃)- and -CH₂CH₂-;



is selected from the group consisting of 1-acenaphthenyl, R-1-acenaphthenyl, S-1-acenaphthenyl, phenyl, 1-naphthyl 2-naphthyl and 1,2,3,4-tetrahydro-naphthyl;

R⁵ is selected from the group consisting of chloro, methyl, n-propyl and trifluoromethyl;


or a pharmaceutically acceptable salt thereof.


5. (Previously Presented) A compound as in Claim 4 wherein

X is -NR¹R²;

R¹ is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, n-


butyl, t-butyl, dimethylaminoethyl, benzyl, phenylethyl,





, 3-methyl-phenyl, 2-(3,4-dimethoxyphenyl)-ethyl, ethoxycarbonyl-methyl, dimethylamino-ethyl and 2-amino-2-methoxycarbonyl-ethyl;

R^2 is selected from the group consisting of hydrogen, methyl, methoxy, ethyl, ethoxycarbonyl-methyl, 2,2,2-trifluoroethyl, ethoxy, dimethylaminoethyl, n-butyl, t-butyl, n-propyl, di(n-butyl)amino-n-propyl, 3-phenyl-n-propyl, cyclopropyl, phenyl, 4-fluorophenyl, 4-methylphenyl, 2-aminophenyl, 4-(t-butoxycarbonylamino-ethyl)-phenyl, 3,4-dimethoxyphenyl, 4-biphenyl, 2-ethoxyphenyl, 4-(aminoethyl)-phenyl, benzyl, benzyloxy, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, 2-methoxybenzyl, 3-methoxybenzyl, 4-methoxybenzyl, 2-ethoxybenzyl, 3-ethoxybenzyl, 2-bromobenzyl, 3-bromobenzyl, 4-bromobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3-iodobenzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-trifluoromethylbenzyl, 3-trifluoromethylbenzyl, 4-trifluoromethylbenzyl, 4-trifluoromethoxybenzyl, 4-methoxycarbonyl-benzyl, 2,3-dimethoxybenzyl, 2,4-dichlorobenzyl, 3,4-dichlorobenzyl, 2,4-difluorobenzyl, 2,5-difluorobenzyl, 3,4-difluorobenzyl, 3,4,5-trimethoxybenzyl, 2,4,6-trimethoxybenzyl, 4-carboxybenzyl, 3-nitrobenzyl, 4-nitrobenzyl, 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl, 3,5-dimethoxybenzyl, 3,4-difluorobenzyl, 3,5-di(trifluoromethyl)-benzyl, 2-phenylethyl, 2-(4-bromophenyl)ethyl, 2-(3-methoxyphenyl)ethyl, 2-(4-methoxyphenyl)ethyl, 2-(3,4-dimethoxyphenyl)ethyl, 2-(2-nitro-4,5-dimethoxyphenyl)ethyl, adamantanyl, 1-adamantanyl-methyl, 1-naphthyl, 1-naphthyl-methyl,



, 2S-hydroxy-S-cyclopentyl-methyl, 2S-hydroxy-S-cyclohexyl-methyl, 2S-hydroxy-S-cycloheptyl-methyl and 2-phenoxy-ethyl;

L^1 is selected from the group consisting of $-CH_2-$ and $-CH_2-CH_2-$;




is selected from the group consisting of 1-acenaphthenyl, R-1-acenaphthenyl, S-1-acenaphthenyl, phenyl-and 1-naphthyl;

p is an integer from 0 to 2;

or a pharmaceutically acceptable salt thereof.


6. (Previously Presented) A compound as in Claim 5 wherein

R¹ is selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, n-butyl, t-butyl, dimethylaminoethyl, benzyl, phenylethyl, 2-(3,4-dimethoxyphenyl)-ethyl,




dimethylamino-ethyl, ethoxycarbonyl-methyl,

and



R² is selected from the group consisting of hydrogen, methyl, methoxy, ethyl, ethoxycarbonyl-methyl, ethoxy, dimethylaminoethyl, n-butyl, n-propyl, di(n-butyl)amino-n-propyl, 3-phenyl-n-propyl, 3-(2-pyridyl)-n-propyl, cyclopropyl, phenyl, 4-fluorophenyl, 4-methylphenyl, 2-aminophenyl, 3,4-dimethoxyphenyl, 4-(t-butoxycarbonylamino-ethyl)-phenyl, 4-biphenyl, 2-ethoxyphenyl, 4-(aminoethyl)-phenyl, benzyl, benzyloxy, 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, 2-methoxybenzyl, 3-methoxybenzyl, 4-methoxybenzyl, 2-ethoxybenzyl, 3-ethoxybenzyl, 2-bromobenzyl, 3-bromobenzyl, 4-bromobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 3-iodobenzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-trifluoromethylbenzyl, 3-trifluoromethylbenzyl, 4-trifluoromethylbenzyl, 4-trifluoromethoxybenzyl, 4-methoxycarbonyl-benzyl, 2,3-dimethoxybenzyl, 2,4-dichlorobenzyl, 3,4-dichlorobenzyl, 2,4-difluorobenzyl, 2,5-difluorobenzyl, 3,4,5-trimethoxybenzyl, 2,4,6-trimethoxybenzyl, 3-nitrobenzyl, 4-nitrobenzyl, 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl, 3,5-dimethoxybenzyl, 3,4-

difluorobenzyl, 3,5-di(trifluoromethyl)-benzyl, 2-phenylethyl, 2-(4-bromophenyl)ethyl, 2-(3-methoxyphenyl)ethyl, 2-(4-methoxyphenyl)ethyl, 2-(3,4-dimethoxyphenyl)ethyl, 2-(2-nitro-4,5-dimethoxy-phenyl)ethyl, 1-adamantanyl, 1-adamantanyl-methyl, 1-naphthyl, 1-



p is an integer from 0 to 1;

R⁵ is selected from the group consisting of methyl, n-propyl and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

7. (Previously Presented) A compound as in Claim 4 wherein

R⁰ is -CH₂-CH(OH)-CH₂-X;

X is -NR¹R²;

R¹ is selected from the group consisting of hydrogen, 2-(3,4-dimethoxyphenyl)-ethyl, 1-(3,4-dimethoxyphenyl)-n-ethyl and amino-n-propyl;

R² is selected from the group consisting of hydrogen, methyl, n-butyl, 3-hydroxy-n-propyl, 3-methoxy-n-propyl, methylamino-n-propyl, dimethylamino-n-propyl, t-butoxycarbonylamino-n-propyl, N-methyl-N-t-butoxycarbonyl-amino-n-ethyl, 3-nitrobenzyl, 4-methoxycarbonyl-benzyl and -CH(CH₃)-phenyl;

R³ is selected from the group consisting of phenyl and 4-fluorophenyl;

L¹ is selected from the group consisting of -CH₂- and -CH₂CH₂-;



is selected from the group consisting 1-naphthyl, 1-acenaphthenyl, R-1-acenaphthenyl and S-1-acenaphthenyl;

p is an integer from 0 to 1;

R⁵ is methyl;

or a pharmaceutically acceptable salt thereof.

8. (Previously Presented) A compound as in Claim 7 wherein

R^1 is selected from the group consisting of hydrogen, 1-(3,4-dimethoxyphenyl)-n-ethyl and amino-n-propyl;

R^2 is selected from the group consisting of hydrogen, methyl, n-butyl, 3-hydroxy-n-propyl, 3-methoxy-n-propyl, methylamino-n-propyl, dimethylamino-n-propyl, N-methyl-N-t-butoxycarbonyl-amino-n-ethyl, 3-nitrobenzyl, 4-methoxycarbonyl-benzyl and -CH(CH₃)-phenyl;



is selected from the group consisting 1-naphthyl, 1-acenaphthenyl, R-1-acenaphthenyl and S-1-acenaphthenyl;

or a pharmaceutically acceptable salt thereof.

9. (Previously Presented) A compound as in Claim 1 selected from the group consisting of

8-(R) acenaphthen-1-yl-3-(3-amino-2-(S)-hydroxy-propyl)-1-(4-fluoro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one;

8-(R) acenaphthen-1-yl-3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one;

8-(R)-Acenaphthen-1-yl-3-(3-dimethylamino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-1,3,8-triaza-spiro[4.5]decan-4-one;

3-(3-Amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one;


3-(3-Dimethylamino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one;

1-(4-Fluoro-phenyl)-3-[2-(R)-hydroxy-3-(3-hydroxy-propylamino)-propyl]-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one;

1-(4-Fluoro-phenyl)-3-[2-(R)-hydroxy-3-(3-methylamino-propylamino)-propyl]-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one;


3-[3-(3-Dimethylamino-propylamino)-2-(R)-hydroxy-propyl]-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and pharmaceutically acceptable salts thereof.

10. (Previously Presented) A compound of the formula (I)



wherein

R^0 is selected from the group consisting of $-\zeta-\begin{array}{c} R^A \\ | \\ C \\ | \\ R^B \end{array}-\begin{array}{c} OH \\ | \\ C \\ | \\ R^A \end{array}-(CR^C R^D)_{1-3}-X$ and



each R^A and R^B is independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

each R^C and R^D is independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

each R^E is independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

X is $-NR^1 R^2$;

each R^1 and R^2 is independently selected from the group consisting of hydrogen, C_{1-8} alkyl, C_{1-8} alkoxy, cycloalkyl, cycloalkyl- C_{1-4} alkyl, partially unsaturated carbocyl, aryl, ar C_{1-4} alkyl, ar C_{1-4} alkoxy, $-C(O)-C_{1-6}$ alkyl, $-C(O)-$ aryl and $-C(O)-$ ar C_{1-4} alkyl; wherein

the C₁₋₆alkyl, cycloalkyl, partially unsaturated carbocyclyl, aryl or arC₁₋₆alkyl group, whether alone or part of a substituent group, is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy, C₁₋₄alkyl, C₁₋₄alkoxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, -C(O)-C₁₋₄alkyl, C₁₋₄alkoxycarbonyl, N(R^E)₂, N(R^E)₂-C₁₋₄alkyl, N(R^E)-C(O)C(CH₃)₃, aryl, aryloxy, cycloalkyl, heteroaryl, aryl substituted heteroarylaminosulfonyl or C₁₋₆alkylthio;

R³ is aryl; wherein the aryl is optionally substituted with one or more substituents independently selected from halogen, hydroxy, carboxy, C₁₋₄alkyl, C₁₋₄alkoxy, trifluoromethyl, trifluoromethoxy, nitro, cyano or N(R^E)₂;

n is an integer from 0 to 2;

R⁴ is selected from the group consisting of hydroxy, C₁₋₄alkyl and hydroxy substituted C₁₋₄alkyl;

m is an integer from 0 to 1;

L¹ is selected from the group consisting of C₁₋₆alkyl and C₃₋₆alkenyl; wherein the double bond of the C₃₋₆alkenyl group is at least one carbon atom removed from the attachment point to the N atom; and wherein the C₁₋₆alkyl or C₃₋₆alkenyl group is optionally substituted with one to two substituents independently selected from hydroxy, fluoro, C₁₋₆alkyl, fluorinated C₁₋₆alkyl or C₁₋₆alkoxy;



is selected from the group consisting of phenyl, naphthyl and acenaphthyl;

p is an integer from 0 to 5;

R⁵ is selected from the group consisting of hydroxy, carboxy, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, nitro, cyano, NR¹R², trifluoromethyl, trifluoromethoxy, C₁₋₄alkoxycarbonyl, -SO-NR¹R², -SO₂-NR¹R² and -C(O)-NR¹R²;

q is 0;

R⁶ is selected from the group consisting of -(L²)₀₋₁-R⁷;

L² is selected from the group consisting of -C₁₋₆alkyl-, -C₂₋₄alkenyl-, -C₂₋₆alkynyl-, -O-, -S-, -NH-, -N(C₁₋₄alkyl)-, -C₁₋₆alkyl-O-, -C₁₋₆alkyl-S-, -O-C₁₋₆alkyl-, -S-C₁₋₆alkyl-, -O-

C₂₋₆alkyl-O-, -S-C₂₋₆alkyl-S-, -SO₂-, -SO₂NH-, -SO₂N(C₁₋₄alkyl)-, -NH-SO₂-, -N(C₁₋₄alkyl)-SO₂-, -C(O)-O- and -O-C(O)-;

R⁷ is selected from the group consisting of aryl, partially unsaturated carbocyclyl, cycloalkyl, heteroaryl and heterocycloalkyl; wherein the aryl, partially unsaturated carbocyclyl, cycloalkyl, heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from hydroxy, carboxy, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, nitro, cyano, N(R^E)₂, trifluoromethyl, trifluoromethoxy, C₁₋₆alkoxycarbonyl, -SO₂-N(R^E)₂ and -C(O)-N(R^E)₂;

or a pharmaceutically acceptable salt thereof.

11. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1.

12. (Original) A pharmaceutical composition made by mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.

13. (Original) A process for making a pharmaceutical composition comprising mixing a compound of Claim 1 and a pharmaceutically acceptable carrier.

Claims 14-21. (Withdrawn)

Claim 22 (New) A compound selected from the group consisting of 3-(3-Amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triazaspiro[4.5]decan-4-one and pharmaceutically acceptable salts thereof.

Claim 23 (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 22.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.